慢性肾脏病患者CYFRA21-1的表达分析

目的探讨细胞角蛋白19的可溶性片段CYFRA21-1在慢性肾脏病（chronic kidney disease,CKD）患者血清中的表达及其临床意义。方法 2008年10月2009年4月随机选取45例CKD患者,根据肌酐清除率（cre-atinine clearance rate,Ccr）的大小分为Ccr〈15mL/min组（23例）和Ccr〉15mL/min组（22例）,并以正常体检者（10例）为正常对照组,肺鳞癌患者（10例）为阳性对照组,每位参与研究者取血后采用酶联免疫吸附法测定血清CY-FRA21-1的浓度。结果正常对照组、阳性对照组、Ccr〉15mL/min组和Ccr〈15mL/min组的血清CFRA21-1浓度分别为（1.720±0.535）、（21.010±11.809）、（3.310±1.569）和（5.090±1.306）ng/mL。与正常对照组比较,其余3组的CYFRA21-1浓度均显著升高,有统计学意义（P〈0.05）,且均值大于正常参考值（0～3.3ng/mL）;Ccr〉15mL/min组和Ccr〈15mL/min组的CFRA21-1浓度显著低于阳性对照组,有统计学意义（P〈0.05）;两个实验组间随着Ccr的降低,CYFRA21-1浓度升高,有统计学意义（P〈0.05）。结论 CKD患者血清CYFRA21-1水平的升高与肾功能减退存在一定关系,可将其作为临床上预测肾脏纤维化程度的指标。

Analysis of Serum Concentration of CYFRA21-1in Chronic Kidney Disease Patients

Objective To discuss the clinical Between significance of cytokeratin 19fragment（CYFRA21-1）in patients with chronic kidney disease（CKD）.Methods From October 2008to April 2009,45inpatients were randomly selected and assigned into three groups according to creatinine clearance rate（Ccr）level：Ccr15mL/min,Ccr 15mL/min.Ten healthy volunteers were chosen as control group,and other 10patients with lung squamous cell carcinoma as positive control group.ELISA was used to measure the serum concentration of CYFRA21-1.Results Compared with control group,the serum concentration of CYFRA21-1in CKD groups and positive control group was elevated（P0.05）.As the Ccr decreased,the serum concentration of CYFRA21-1was elevated（P0.05）in two CKD groups.Conclusion Serum concentration of CYFRA21-1in CKD patients has a relationship with the renal function decrease,and may be used as an indication of renal interstitial fibrosis（RIF）.